Intellipharmaceutics International Inc. – OTC:IPCIF

Intellipharmaceutics International stock price today

$0.055
-0.09
-63.33%
Financial Health
0
1
2
3
4
5
6
7
8
9

Intellipharmaceutics International stock price monthly change

+604.23%
month

Intellipharmaceutics International stock price quarterly change

+97.06%
quarter

Intellipharmaceutics International stock price yearly change

+212.50%
year

Intellipharmaceutics International key metrics

Market Cap
2.21M
Enterprise value
3.91M
P/E
-0.46
EV/Sales
38.16
EV/EBITDA
-1.16
Price/Sales
19.37
Price/Book
-0.19
PEG ratio
0.02
EPS
-0.19
Revenue
N/A
EBITDA
-3.91M
Income
-5.60M
Revenue Q/Q
-100%
Revenue Y/Y
-97.31%
Profit margin
-3877.64%
Oper. margin
-3696.77%
Gross margin
0%
EBIT margin
-3696.77%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Intellipharmaceutics International stock price history

Intellipharmaceutics International stock forecast

Intellipharmaceutics International financial statements

Intellipharmaceutics International Inc. (OTC:IPCIF): Profit margin
Feb 2021 0 -924.56K
May 2021 93.42K -1.00M -1070.55%
Aug 2021 0 -1.23M
Nov 2021 0 -2.44M
Intellipharmaceutics International Inc. (OTC:IPCIF): Debt to assets
Feb 2022 1889571 10.90M 577.11%
May 2022 1881583 11.73M 623.81%
Aug 2022 1437022 11.58M 806.46%
Nov 2022 1432032 12.00M 838.58%
Intellipharmaceutics International Inc. (OTC:IPCIF): Cash Flow
Feb 2021 623 0 0
May 2021 -763.76K 0 3.03M
Aug 2021 -1.36M 0 0
Nov 2021 -335.75K 0 0

Intellipharmaceutics International alternative data

Intellipharmaceutics International Inc. (OTC:IPCIF): Employee count
Aug 2023 11
Sep 2023 11
Oct 2023 11
Nov 2023 11
Dec 2023 11
Jan 2024 11
Feb 2024 11
Mar 2024 11
Apr 2024 11
May 2024 11
Jun 2024 11
Jul 2024 11

Intellipharmaceutics International other data

  • What's the price of Intellipharmaceutics International stock today?

    One share of Intellipharmaceutics International stock can currently be purchased for approximately $0.06.

  • When is Intellipharmaceutics International's next earnings date?

    Unfortunately, Intellipharmaceutics International's (IPCIF) next earnings date is currently unknown.

  • Does Intellipharmaceutics International pay dividends?

    No, Intellipharmaceutics International does not pay dividends.

  • How much money does Intellipharmaceutics International make?

    Intellipharmaceutics International has a market capitalization of 2.21M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 95.31% to 65.73K US dollars.

  • What is Intellipharmaceutics International's stock symbol?

    Intellipharmaceutics International Inc. is traded on the OTC under the ticker symbol "IPCIF".

  • What is Intellipharmaceutics International's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Intellipharmaceutics International?

    Shares of Intellipharmaceutics International can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Intellipharmaceutics International have?

    As Jul 2024, Intellipharmaceutics International employs 11 workers.

  • When Intellipharmaceutics International went public?

    Intellipharmaceutics International Inc. is publicly traded company for more then 29 years since IPO on 19 Aug 1996.

  • What is Intellipharmaceutics International's official website?

    The official website for Intellipharmaceutics International is intellipharmaceutics.com.

  • Where are Intellipharmaceutics International's headquarters?

    Intellipharmaceutics International is headquartered at 30 Worcester Road, Toronto, ON.

  • How can i contact Intellipharmaceutics International?

    Intellipharmaceutics International's mailing address is 30 Worcester Road, Toronto, ON.

Intellipharmaceutics International company profile:

Intellipharmaceutics International Inc.

intellipharmaceutics.com
Exchange:

OTC

Full time employees:

11

Industry:

Biotechnology

Sector:

Healthcare

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

30 Worcester Road
Toronto, ON M9W 5X2

CIK: 0001474835
ISIN: CA4581733090
CUSIP: 458173309